Eton Pharmaceuticals, Inc. 8-K

What Happened
Eton Pharmaceuticals, Inc. announced on April 27, 2026 that a pilot clinical study is underway for its product candidate ET-700, an extended‑release formulation of zinc acetate, to be compared with Galzin® and a placebo for the treatment of Wilson disease. The company issued a press release describing the study, which is attached as Exhibit 99.1 to the Form 8-K filed on that date.

Key Details

• Date of disclosure: April 27, 2026 (Form 8-K, Item 8.01 — Other Events).
• Product candidate: ET-700 — an extended‑release formulation of zinc acetate.
• Study design note: Pilot study comparing ET-700 to Galzin® (zinc acetate) and placebo for treatment of Wilson disease.
• Press release announcing the study is included as Exhibit 99.1 to the 8-K.

Why It Matters
This filing provides a material clinical development update: Eton has moved ET-700 into a pilot clinical study comparing it directly to an existing zinc acetate product and placebo. Investors monitor such study initiations because they mark progress in a drug candidate’s development program and can influence timelines, regulatory planning, and future company disclosures. The company formally disclosed the update through a press release attached to the 8-K.